Danegaptide
- Generic Name
- Danegaptide
- Drug Type
- Small Molecule
- Chemical Formula
- C14H17N3O4
- CAS Number
- 943134-39-2
- Unique Ingredient Identifier
- PA0Y7735AT
- Background
Danegaptide has been investigated for the treatment of Focus of Study is STEMI.
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 591
- Registration Number
- NCT01977755
- Locations
- 🇩🇰
The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00783341
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
Phase 1
Completed
- Conditions
- Arrhythmia
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00543946
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00510029
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath